Mirodenafil

Mirodenafil is an orally active, selective inhibitor of phosphodiesterase type 5 (PDE5), the enzyme family central to the treatment of erectile dysfunction. Developed by the Korean company SK Chemicals under the research code SK3530, it is chemically a pyrimidinone sulfonamide derivative and was approved in South Korea in 2007, where it is sold as Mvix ^[1][4]. It belongs to the same pharmacological class as sildenafil and tadalafil but is distinguished by relatively high water solubility and a short duration of action suited to on-demand use ^[4].

Its clinical evidence base is built on multicenter, randomized, double-blind, placebo-controlled trials conducted largely in Korean men. A pivotal fixed-dose study in 223 men with erectile dysfunction of varied causes showed significant improvement across the International Index of Erectile Function and related measures, with most adverse events mild and self-limiting ^[1]. Further trials extended these findings to harder-to-treat populations, including men with diabetes, and a later meta-analysis pooled three randomized trials to confirm consistent efficacy and good tolerability ^[2][3].

Beyond erectile dysfunction, mirodenafil has been investigated for lower urinary tract symptoms associated with benign prostatic hyperplasia and studied in combination with alpha-blocker therapy, where it improved symptoms and sexual function without meaningful blood pressure interaction ^[6]. Preclinical pharmacokinetic work has mapped its absorption, first-pass metabolism, and two principal metabolites ^[5].

From a regulatory standpoint, mirodenafil is an approved medicine in South Korea and some other markets but has not been approved by the US Food and Drug Administration or the European Medicines Agency, so outside its approved territories it circulates as a research chemical and gray-market compound. It is formulated as oral tablets, including orally disintegrating forms ^[4].

As a PDE5 inhibitor, mirodenafil must never be combined with nitrates or guanylate-cyclase stimulators, as the combination can cause dangerous, potentially fatal drops in blood pressure. Common effects include headache, facial flushing, indigestion, and nasal congestion, while rare but serious risks include a prolonged painful erection (priapism) requiring emergency care and sudden vision or hearing loss. Caution and dose adjustment are needed with alpha-blockers and strong CYP3A4 inhibitors.

Mirodenafil is a second-generation phosphodiesterase type 5 inhibitor developed in South Korea by SK Chemicals, where it was known during development by the code SK3530. It was approved by Korean regulators and launched for erectile dysfunction under the brand name Mvix in 2007, making it one of a small number of PDE5 inhibitors developed outside the major Western pharmaceutical companies. The compound was designed for high selectivity for PDE5 over related isoenzymes and for a short plasma half-life suited to on-demand use. Its clinical program included several multicenter, randomized, double-blind, placebo-controlled trials in Korean men, including studies in difficult-to-treat populations such as diabetic patients. It remains most widely used in South Korea and is not approved in the United States or Europe.

Among the PDE5 inhibitors, mirodenafil has a solid, evidence-backed reputation as an effective and well-tolerated on-demand treatment for erectile dysfunction. A meta-analysis of three randomized controlled trials found it markedly superior to placebo, and it performed respectably even in diabetic men, a group that often responds poorly to this drug class. Its high selectivity for PDE5 over the PDE6 isoform linked to visual side effects is often cited as a favorable feature. Users and clinicians appreciate a side-effect profile dominated by mild, transient flushing and headache. Its main limitation is geographic; because it is chiefly a Korean product, it is far less familiar and less accessible than sildenafil or tadalafil, and long-term data across diverse populations remain more limited.